Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024
Save time and jump to the most important pieces.
4 - CervoMed Inc. (0001053691) (Issuer)
3 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of to
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (D
LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and cert
SC 13G/A - CervoMed Inc. (0001053691) (Subject)
SC 13D - CervoMed Inc. (0001053691) (Subject)
SC 13G - CervoMed Inc. (0001053691) (Subject)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately. Ms. Jaeger will be responsible for development and implementation of regulatory and related strategies to support the development and commercialization of Diffusion's product development candidates, including the Company's lead candidate, trans sodium crocetinate (TSC), which is planned for development as an adju
Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable SecuritiesRegained Compliance with Nasdaq Bid Price Rule CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended March 31, 2022, and provided a business update. Business Updates Completed Dosin
Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of
On Thursday, 109 companies set new 52-week lows. 52-Week Low Highlights: The largest company in terms of market cap to set a new 52-week low was Nasdaq (NASDAQ:NDAQ). Biodexa Pharmaceuticals (NASDAQ:BDRX) was the smallest company in terms of market cap to set a new 52-week low. Sarcos Technology (NASDAQ:STRC) shares dropped the most, trading down 417.35% to reach its new 52-week low. Cineverse (NASDAQ:CNVS) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Here is a list of stocks that set new 52-week lows on Thursday: Nasdaq (NASDAQ:NDAQ) stock achieved a new 52-week low on Thursday morning, hitting $48.90 and moving down 1.92%. Jazz P
Friday's session saw 100 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: BioNTech (NASDAQ:BNTX) was the largest, in terms of market cap, to set a new 52-week low. Vyant Bio (NASDAQ:VYNT) was the smallest, in terms of market cap, to set a new 52-week low. Soligenix (NASDAQ:SNGX)'s stock came under the most pressure, trading down 47.37% to reach a new 52-week low. Barings BDC (NYSE:BBDC) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. On Friday, the following stocks broke to new 52-week lows: BioNTech (NASDAQ:BNTX) stock achieved a new 52-week low on Friday morning, hitting $1